BioSpace News Archive

Genetown

Nimbus Therapeutics Raises Another $65 Million from Lilly, Bill Gates, Pfizer and Others

Nimbus Therapeutics, raised an additional $65 million in financing.

June 5, 2018
·
3 min read
·
Mark Terry
Business

ABC’s Robin Roberts Kicks Off BIO Convention with Keynote Speech

Robin Roberts, ABC’s Good Morning America journalist and anchor, kicked off the 2018 BIO International Convention in Boston with her keynote address.

June 5, 2018
·
3 min read
·
Mark Terry
Drug Development

Tricida Files $150M IPO, Shares Kidney Drug Trial Results

Tricida, a late-stage biotech company developing therapies for conditions associated with chronic kidney disease (CKD), filed late Monday with the Securities and Exchange Commission to raise up to $150 million in an initial public offering.

June 5, 2018
·
2 min read
·
Don McCormick
Business

Portola Pharmaceuticals’ CEO to Step Down

Portola Pharmaceuticals’ chief executive officer, William Lis, plans to retire as both chief executive and board member.

June 5, 2018
·
3 min read
·
Mark Terry
FDA

FDA Approves Mylan’s Biosimilar to Amgen’s Neulasta

The U.S. Food and Drug Administration (FDA) approved Mylan’s Fulphila (pegfilgrastim-jmbd), a biosimilar to Amgen’s Neulasta (pegfilgrastim). The biosimilar was co-developed with Biocon.

June 5, 2018
·
2 min read
·
Mark Terry
Drug Development

Germany-Based Companies Open Lab Space in U.S.

There are several recent announcements of German companies opening laboratories in the U.S.

June 5, 2018
·
3 min read
·
Mark Terry
Business

Hookipa Biotech and Gilead Ink Deal to Develop HIV and Hepatitis B Therapies

Hookipa Biotech and Gilead inked a research collaboration deal to develop and commercialize therapeutics for hepatitis B (HBV) and HIV.

June 5, 2018
·
3 min read
·
Mark Terry
Business

Horizon Pharma and NORD Celebrate Anniversary of the Orphan Drug Act

Horizon Pharma and the National Organization for Rare Disorders (NORD) launched a new campaign today that recognizes innovation in rare disease therapeutics since the passing of the Orphan Drug Act in 1983.

June 5, 2018
·
3 min read
·
Mark Terry
Drug Development

AbbVie’s Upadacitinib Looks Good in Arthritis Trial; Rova-T Looks Worse in Lung Cancer

AbbVie announced positive topline results from its SELECT-EARLY Phase III clinical trial in rheumatoid arthritis, but disappointed with Rova-T small-cell lung cancer therapy.

June 5, 2018
·
2 min read
·
Mark Terry
TRiCares Closes €22 Million ($25.4 Million) Series B Financing Round to Fund Development of Minimally Invasive Treatment of Tricuspid Regurgitation

TRiCares SAS is pleased to announce today the successful completion of a €22 Million ($25.4 Million) Series B financing round.

June 5, 2018
·
4 min read